Ucb SA - ESG Rating & Company Profile powered by AI
Alternative companies in the rating industry group for Ucb SA are displayedin the table. The ESG score includes seventeen UN Sustainable Development Goals including: 'Affordable & Clean Energy', 'Climate Action' and 'Peace, Justice & Strong Institutions'. If you are employed by Ucb SA and you wish to use your ESG rating, please get in touch.
Ucb SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.9; made up of an environmental score of 4.0, social score of 6.0 and governance score of 4.6.
4.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 744 | Sopharma AD | 5.0 | High |
| 744 | vTv Therapeutics Inc | 5.0 | High |
| 764 | Ucb SA | 4.9 | High |
| 764 | BetterLife Pharma Inc | 4.9 | High |
| 764 | Acerus Pharmaceuticals Corporation | 4.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ucb SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ucb SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Ucb SA report the average age of the workforce?
Sign up for free to unlockDoes Ucb SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ucb SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ucb SA disclose cybersecurity risks?
Sign up for free to unlockDoes Ucb SA offer flexible work?
Sign up for free to unlockDoes Ucb SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ucb SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ucb SA conduct supply chain audits?
Sign up for free to unlockDoes Ucb SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ucb SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ucb SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ucb SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ucb SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ucb SA disclose water use targets?
Sign up for free to unlockDoes Ucb SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Ucb SA have a product recall in the last two years?
Sign up for free to unlockDoes Ucb SA disclose incidents of discrimination?
Sign up for free to unlockDoes Ucb SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ucb SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ucb SA disclose parental leave metrics?
Sign up for free to unlockDoes Ucb SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ucb SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ucb SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ucb SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ucb SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ucb SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ucb SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Ucb SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ucb SA disclose its waste policy?
Sign up for free to unlockDoes Ucb SA report according to TCFD requirements?
Sign up for free to unlockDoes Ucb SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ucb SA disclose energy use targets?
Sign up for free to unlockDoes Ucb SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ucb SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ucb SA
These potential risks are based on the size, segment and geographies of the company.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.